SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sørensen, P. S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sørensen, P. S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Intravenous immunoglobulin G therapy: effects of acute and chronic treatment in multiple sclerosis

Per Soelberg Sørensen

Copenhagen Multiple Sclerosis Clinic, Department of Neurology, National University Hospital, Rigshospitalet, Copenhagen, Denmark

High dose intravenous immunoglobulin (IVIG) exerts several effects on the immune system that could have a beneficial influence on the disease processes in multiple sclerosis (MS). IVIG may by useful in treatment of acute exacerbations, in prevention of new relapses, and in promotion of remyelination. Presently, the clinical evidence of effect of IVIG in MS is based on the results of small open trials, some of which, however, have been encouraging. Confirmation of a beneficial effect of IVIG must await the results of placebo-controlled, double-blind trials currently ongoing in several centers. If effective, IVIG administration would be a valuable supplement to the existing treatment of MS.

Key Words: IgG • intravenous immunoglobulins • multiple sclerosis • multiple sclerosis therapy

Multiple Sclerosis, Vol. 1, No. 6, 349-352 (1996)
DOI: 10.1177/135245859600100614
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement